Session Details
[O-21]Oral Session 21 Neuromuscular junction disease 2
Thu. May 22, 2025 9:45 AM - 10:45 AM JST
Thu. May 22, 2025 12:45 AM - 1:45 AM UTC
Thu. May 22, 2025 12:45 AM - 1:45 AM UTC
第13会場(リーガロイヤルホテル大阪3F 光琳の間①)
Chair: Yasushi Suzuki(National Hospital Organization Sendai Medical Center, Japan)
[O-21-1]Safety of Intravenous Methylprednisolone Pulse Therapy for Ocular Myasthenia Gravis
Tomoko Tanaka, Jun Kozuki, Ryosuke Sugisawa, Syun Matoba, Hirotomo Suehiro, Kento Matoba, Mayumi Otani, Shusuke Koto, Yoshikatsu Noda, Norio Chihara, Kenji Sekiguchi (Division of Neurology, Kobe University Graduate School of Medicine, Japan)
[O-21-2]Treatment patterns of patients with late elderly-onset myasthenia gravis
Akiyuki Uzawa1, Shingo Konno2, Makoto Samukawa3, Izumi Mishiro4, Hiroshi Todaka4, Kentaro Taki4, Kunihiko Shiraiwa4, Yohei Ohashi4 (1.Department of Neurology, Graduate School of Medicine, Chiba University, Japan, 2.Department of Neurology, Toho University Ohashi Medical Center, Japan, 3.Department of Neurology, Kindai University Faculty of Medicine, Japan, 4.UCB, Tokyo Japan, Japan)
CAREER
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008- Department of Neurology, Chiba University Hospital
SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)
Editorial committee member of Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome
AWARDS
2022 Japanese Society for Neuroimmunology, Research and Creation Award
2022 Japanese Society of Neurological Therapeutics, Therapeutic Academic Award
2022 Best Oral Presentation Award, Japanese Society of Neurological Therapeutics
2018 Best Oral Presentation Award, Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008- Department of Neurology, Chiba University Hospital
SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)
Editorial committee member of Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome
AWARDS
2022 Japanese Society for Neuroimmunology, Research and Creation Award
2022 Japanese Society of Neurological Therapeutics, Therapeutic Academic Award
2022 Best Oral Presentation Award, Japanese Society of Neurological Therapeutics
2018 Best Oral Presentation Award, Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement
[O-21-3]Predicting achievement of clinical goals using machine learning in myasthenia gravis
Hiroyuki Akamine1, Akiyuki Uzawa1, Satoshi Kuwabara1, Yosuke Onishi1, Manato Yasuda1, Yukiko Ozawa1, Naoki Kawaguchi1, Tomoya Kubota2, Masanori Takahashi2, Shigeaki Suzuki3, Masayuki Masuda4, Shingo Konno5, Naoya Minami6, Takashi Kimura7, Makoto Samukawa8, Yasushi Suzuki9, Gennya Watanabe9, Yuriko Nagane10, Kimiaki Utsugisawa10 (1.Graduate School of Medicine, Chiba University Neurology, Japan, 2.Department of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Japan, 3.Department of Neurology, Keio University School of Medicine, Japan, 4.Department of Neurology, Tokyo Medical University, Japan, 5.Department of Neurology, Toho University Ohashi Medical Center, Japan, 6.National Hospital Organization Hokkaido Medical Center, Japan, 7.Department of Neurology, Hyogo Medical University, Japan, 8.Department of Neurology, Kindai University Faculty of Medicine, Japan, 9.Department of Neurology, National Hospital Organization Sendai Medical Center, Sendai, Japan, Japan, 10.Department of Neurology, Hanamaki General Hospital, Japan)
[O-21-4]Long-term safety and efficacy of zilucoplan in gMG: 120-week interim analysis of RAISE-XT [Encore Presentation]
James F. Howard Jr.1, Miriam Freimer2, Angela Genge3, Channa Hewamadduma4,5, Yessar Hussain6, Angelina Maniaol7, Renato Mantegazza8, Kimiaki Utsugisawa9, Tuan Vu10, Michael D. Weiss11, Babak Boroojerdi12, Petra W. Duda12, Fiona Grimson12, Mark Vanderkelen12, M. Isabe Leite13 (1.Department of Neurology, The University of North Carolina at Chapel Hill, USA, 2.Department of Neurology, The Ohio State University Wexner Medical Center, USA, 3.Clinical Research Unit, The Montreal Neurological Institute, Canada, 4.Academic Neuroscience Unit, Sheffield Teaching Hospitals NHS Foundation Trust, UK, 5.Sheffield Institute for Translational Neurosciences (SITraN), University of Sheffield, UK, 6.Department of Neurology, Dell Medical School, The University of Texas at Austin, USA, 7.Department of Neurology, Oslo University Hospital, Norway, 8.Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Italy, 9.Department of Neurology, Hanamaki General Hospital, Japan, 10.Department of Neurology, University of South Florida Morsani College of Medicine, USA, 11.Department of Neurology, University of Washington Medical Center, USA, 12.UCB, Belgium, 13.Nuffield Department of Clinical Neurosciences, University of Oxford, UK)